Gary D. Glick, Ph.D.
Scorpion Founder
University of Michigan Medical School
Dr. Glick is a chemist and biotech entrepreneur with over 15 years of experience in the biotech industry. He started his career at the University of Michigan in Ann Arbor,…
Dr. Glick is a chemist and biotech entrepreneur with over 15 years of experience in the biotech industry. He started his career at the University of Michigan in Ann Arbor, where he is currently the Warner E. Bachmann professor emeritus of chemistry. He has founded several successful companies, including IFM Therapeutics. While Dr. Glick was CEO of IFM, the company progressed three programs from ideation to clinical development and executed several major transactions, including the sale of oncology assets to Bristol-Myers Squibb and the sale of an NLRP3 inhibitor program to Novartis.
In 2020, Dr. Glick co-founded Scorpion Therapeutics, where he played an instrumental role in the conception and building of the company. During his tenure as CEO, Scorpion grew to nearly 50 employees and raised $270 million across two financings. In 2021, he founded Odyssey Therapeutics to discover and develop medicines that advance the standard of care for patients living with autoimmune diseases and cancer.
Dr. Glick received his Ph.D. in organic chemistry from Columbia University and completed an NIH postdoctoral fellowship in organic chemistry at Harvard University. He is the author of more than 100 papers, the inventor on 54 issued U.S. patents, and the recipient of numerous awards recognizing his scientific contributions and accomplishments.